For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

一种新的肥胖症治疗方法不再以神经元为靶点，而是针对大脑中的支持细胞，从而在不引起恶心的情况下实现减重和更好的血糖控制。人体试验有望在几年内开始。 目前市场上的减肥和糖尿病药物通常无法帮助患者实现长期减重。胰高血糖素样肽-1（Glucagon-like ...

三项最新研究表明，胰高血糖素样肽-1（Glucagon-like peptide-1, GLP-1）药物，如 Ozempic（奥земпик），可能显著降低中风死亡率，改善脑损伤后的恢复，并可能降低整体中风风险。 在神经介入手术学会（Society ...

In this cohort study of individuals with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use was associated with a modestly increased risk of incident diabetic retinopathy ...

In this cohort study of individuals with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use was ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...